This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety
of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic
While GT (Gemcitabine + Nab-paclitaxel) is one of the preferred regimens for metastatic
pancreatic cancer, we have yet to determine the optimum number of cycles for GT treatment
regimen. In this single arm, open-label clinical trial, metastatic pancreatic cancer patients
will be received nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) and gemcitabine 1000 mg/m^2 for 3
weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the
disease recurrence or unacceptable toxicity, death or begin a novel therapeutic.
The safety and efficacy of each group will be assessed through ORR, PFS, OS and adverse
effects as graded by CTC-AE 5.0.
Metastatic Pancreatic Cancer
Paclitaxel for Injection（Albumin Bound）
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.